Key ACA architect now supports single-payer

Former U.S. Sen. Max Baucus, D-Montana, was a major player in crafting the Affordable Care Act (ACA) in 2009 when he was chairman of the Senate Finance Committee. Though he then insisted a single-payer healthcare system not be discussed as part of the ACA, he’s now in favor of such a move.

“My personal view is we’ve got to start looking at single-payer,” Baucus said at an event at Montana State University according to the Bozeman Daily Chronicle. “I think we should have hearings…. We’re getting there. It’s going to happen.”

When the ACA was being debated, Baucus was credited with making the final bill more centrist, opposing the inclusion publicly-run insurance option and refusing a hold a hearing on single-payer. He was later criticized for those positions because of the nearly $4 million in campaign contributions he had received from the insurance and pharmaceutical industries.

Now out of political office, Baucus credited some of his change of heart to seeing how Canada’s healthcare system operates. In Montana, he said, half a rural hospital’s space may be dedicated to processing claims. In Canada, all facilities need is a small room to verify a patient’s residency.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.